| NCT03314974 |
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
https://ClinicalTrials.gov/show/NCT03314974 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2025-01-10 |
| NCT03223610 |
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03223610 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-09-01 |
| NCT03038672 |
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03038672 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT03015896 |
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03015896 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-04-30 |
| NCT02996773 |
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine |
https://ClinicalTrials.gov/show/NCT02996773 |
Recruiting |
University of Arizona |
2022-11-29 |
| NCT02950220 |
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02950220 |
Completed |
Ohio State University Comprehensive Cancer Center |
2018-11-19 |
| NCT02797470 |
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02797470 |
Recruiting |
AIDS Malignancy Consortium |
2021-09-30 |
| NCT02722668 |
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
https://ClinicalTrials.gov/show/NCT02722668 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2028-05-31 |
| NCT02669017 |
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) |
https://ClinicalTrials.gov/show/NCT02669017 |
Completed |
ADC Therapeutics S.A. |
2019-02-21 |
| NCT02661035 |
Allo HSCT Using RIC for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT02661035 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-03-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT01028716 |
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01028716 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2024-01-04 |
| NCT01925131 |
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia |
https://ClinicalTrials.gov/show/NCT01925131 |
Active, not recruiting |
Southwest Oncology Group |
2022-01-31 |
| NCT02568553 |
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02568553 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT01092182 |
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01092182 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2021-02-28 |
| NCT02483000 |
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT02483000 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2019-11-17 |
| NCT02481310 |
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02481310 |
Active, not recruiting |
Northwestern University |
2021-07-31 |
| NCT02443831 |
CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT02443831 |
Active, not recruiting |
University College, London |
2020-10-31 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02393157 |
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL |
https://ClinicalTrials.gov/show/NCT02393157 |
Recruiting |
New York Medical College |
2020-12-31 |
| NCT02337985 |
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02337985 |
Active, not recruiting |
City of Hope Medical Center |
2022-06-30 |
| NCT02199184 |
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia |
https://ClinicalTrials.gov/show/NCT02199184 |
Recruiting |
M.D. Anderson Cancer Center |
2022-12-31 |
| NCT02153580 |
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT02153580 |
Recruiting |
City of Hope Medical Center |
2021-12-31 |
| NCT02134782 |
Yoga Fatigue Study |
https://ClinicalTrials.gov/show/NCT02134782 |
Recruiting |
The Hospital for Sick Children |
2023-10-31 |
| NCT01314014 |
Imexon for Relapsed Follicular and Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT01314014 |
Completed |
University of Rochester |
2013-03-31 |
| NCT01290120 |
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt’s Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01290120 |
Completed |
Northern Italy Leukemia Group |
2014-06-30 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT01962636 |
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
https://ClinicalTrials.gov/show/NCT01962636 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-10-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01943682 |
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma |
https://ClinicalTrials.gov/show/NCT01943682 |
Completed |
Children’s Hospital Medical Center, Cincinnati |
2019-03-31 |
| NCT01897012 |
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01897012 |
Completed |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01842672 |
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia |
https://ClinicalTrials.gov/show/NCT01842672 |
Recruiting |
New York Medical College |
2019-12-31 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01815749 |
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01815749 |
Active, not recruiting |
City of Hope Medical Center |
2020-10-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01791595 |
A Phase I Trial of AZD3965 in Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT01791595 |
Active, not recruiting |
Cancer Research UK |
2021-05-31 |
| NCT01786135 |
A Safety Study of SGN-CD19A for B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01786135 |
Completed |
Seattle Genetics, Inc. |
2015-08-31 |
| NCT01786096 |
A Safety Study of SGN-CD19A for Leukemia and Lymphoma |
https://ClinicalTrials.gov/show/NCT01786096 |
Completed |
Seattle Genetics, Inc. |
2017-05-30 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01722305 |
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma |
https://ClinicalTrials.gov/show/NCT01722305 |
Completed |
Mayo Clinic |
2016-06-03 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01597778 |
Double Cord Versus Haploidentical (BMT CTN 1101) |
https://ClinicalTrials.gov/show/NCT01597778 |
Active, not recruiting |
Medical College of Wisconsin |
2020-06-30 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01474681 |
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01474681 |
Completed |
Novartis |
2016-10-03 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01397825 |
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine |
https://ClinicalTrials.gov/show/NCT01397825 |
Completed |
Takeda |
2015-02-05 |
| NCT01363128 |
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
https://ClinicalTrials.gov/show/NCT01363128 |
Completed |
M.D. Anderson Cancer Center |
2020-01-30 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04191187 |
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04191187 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-12-31 |
| NCT03833180 |
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03833180 |
Recruiting |
VelosBio Inc. |
2021-03-31 |
| NCT03793140 |
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations |
https://ClinicalTrials.gov/show/NCT03793140 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-12-31 |
| NCT03677128 |
Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment |
https://ClinicalTrials.gov/show/NCT03677128 |
Recruiting |
Duke University |
2021-06-30 |
| NCT03674411 |
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy |
https://ClinicalTrials.gov/show/NCT03674411 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2023-07-31 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01231919 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
https://ClinicalTrials.gov/show/NCT01231919 |
Completed |
National Cancer Institute (NCI) |
2013-04-30 |
| NCT01184885 |
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy |
https://ClinicalTrials.gov/show/NCT01184885 |
Completed |
Thomas Jefferson University |
2011-03-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01109069 |
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT01109069 |
Completed |
Pharmacyclics LLC. |
2019-04-26 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT00994500 |
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
https://ClinicalTrials.gov/show/NCT00994500 |
Completed |
National Cancer Institute (NCI) |
2011-07-31 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00867529 |
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00867529 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-03-31 |
| NCT00864227 |
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) |
https://ClinicalTrials.gov/show/NCT00864227 |
Completed |
Medical College of Wisconsin |
2011-04-30 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00849147 |
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) |
https://ClinicalTrials.gov/show/NCT00849147 |
Completed |
Medical College of Wisconsin |
2011-06-30 |
| NCT00807495 |
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00807495 |
Completed |
Takeda |
2011-01-04 |
| NCT01859819 |
Treatment for Advanced B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01859819 |
Recruiting |
New York Medical College |
2019-06-30 |
| NCT01789255 |
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01789255 |
Completed |
National Cancer Institute (NCI) |
2014-03-31 |
| NCT01434472 |
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01434472 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2020-07-24 |
| NCT03136146 |
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia |
https://ClinicalTrials.gov/show/NCT03136146 |
Recruiting |
M.D. Anderson Cancer Center |
2025-08-01 |
| NCT03810196 |
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT |
https://ClinicalTrials.gov/show/NCT03810196 |
Recruiting |
Children’s Hospital of Philadelphia |
2024-01-31 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00719888 |
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease |
https://ClinicalTrials.gov/show/NCT00719888 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-12-31 |
| NCT00669877 |
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt’s and Burkitt’s -Like Leukemia/Lymphoma |
https://ClinicalTrials.gov/show/NCT00669877 |
Completed |
M.D. Anderson Cancer Center |
2015-10-31 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00412243 |
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients |
https://ClinicalTrials.gov/show/NCT00412243 |
Completed |
M.D. Anderson Cancer Center |
2012-04-30 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00392990 |
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt’s Lymphoma or Burkitt-Like Lymphoma |
https://ClinicalTrials.gov/show/NCT00392990 |
Completed |
Northwestern University |
2011-12-03 |
| NCT00392834 |
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00392834 |
Completed |
AIDS Malignancy Consortium |
2011-07-31 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00388193 |
Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma |
https://ClinicalTrials.gov/show/NCT00388193 |
Completed |
PETHEMA Foundation |
2013-12-31 |
| NCT00363272 |
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00363272 |
Completed |
National Cancer Institute (NCI) |
2008-10-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00303953 |
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00303953 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00290472 |
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00290472 |
Completed |
National Cancer Institute (NCI) |
2010-04-30 |
| NCT00275080 |
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00275080 |
Completed |
National Cancer Institute (NCI) |
2009-11-30 |
| NCT00217412 |
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia |
https://ClinicalTrials.gov/show/NCT00217412 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00199082 |
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt’s Non-Hodgkin’s Lymphoma (NHL) and Other High-grade Lymphoma in Adults |
https://ClinicalTrials.gov/show/NCT00199082 |
Completed |
Johann Wolfgang Goethe University Hospital |
2010-06-30 |
| NCT00187161 |
Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL |
https://ClinicalTrials.gov/show/NCT00187161 |
Completed |
St. Jude Children’s Research Hospital |
NA |
| NCT00133991 |
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt’s Lymphoma or Leukemia |
https://ClinicalTrials.gov/show/NCT00133991 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2011-08-31 |
| NCT00119392 |
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00119392 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-07-31 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00118170 |
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function |
https://ClinicalTrials.gov/show/NCT00118170 |
Completed |
National Cancer Institute (NCI) |
2007-05-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00110071 |
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00110071 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00109824 |
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00109824 |
Completed |
National Cancer Institute (NCI) |
2009-03-31 |
| NCT00105001 |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00105001 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-05-31 |
| NCT00101270 |
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00101270 |
Completed |
National Cancer Institute (NCI) |
2007-09-30 |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00003166 |
Bryostatin and Vincristine in B-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT00003166 |
Completed |
National Cancer Institute (NCI) |
2001-07-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00073918 |
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00073918 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-10-02 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00064246 |
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder |
https://ClinicalTrials.gov/show/NCT00064246 |
Completed |
National Cancer Institute (NCI) |
2004-09-30 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00060372 |
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer |
https://ClinicalTrials.gov/show/NCT00060372 |
Completed |
National Cancer Institute (NCI) |
2008-04-30 |
| NCT00058019 |
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00058019 |
Completed |
National Cancer Institute (NCI) |
2010-08-31 |
| NCT00057811 |
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma |
https://ClinicalTrials.gov/show/NCT00057811 |
Completed |
Children’s Oncology Group |
2009-10-31 |
| NCT00054639 |
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00054639 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00054483 |
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction |
https://ClinicalTrials.gov/show/NCT00054483 |
Completed |
National Cancer Institute (NCI) |
2009-09-30 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00040690 |
Combination Chemotherapy in Treating Patients With Burkitt’s Lymphoma or Burkitt’s Leukemia |
https://ClinicalTrials.gov/show/NCT00040690 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00039130 |
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt’s Lymphoma or Burkitt’s Leukemia |
https://ClinicalTrials.gov/show/NCT00039130 |
Completed |
Alliance for Clinical Trials in Oncology |
2010-09-30 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00016094 |
S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00016094 |
Completed |
National Cancer Institute (NCI) |
2005-08-31 |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00010192 |
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00010192 |
Completed |
National Cancer Institute (NCI) |
2003-01-31 |
| NCT00006473 |
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00006473 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00002649 |
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00002649 |
Completed |
National Cancer Institute (NCI) |
2006-11-30 |
| NCT00001237 |
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00001237 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001337 |
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00001337 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-03-31 |